Journal of cancer research and clinical oncology
Jun 12, 2025
PURPOSE: This study aimed to evaluate radiomic models' ability to predict hypoxia-related biomarker expression in clear cell renal cell carcinoma (ccRCC).
BACKGROUND: Next-generation sequencing (NGS) has become a cornerstone of treatment for lung cancer and is recommended in current treatment guidelines for patients with advanced or metastatic disease.
Journal of chemical information and modeling
Jun 9, 2025
Patients with locally advanced laryngeal and hypopharyngeal squamous cell carcinoma (LA-LHSCC) urgently need precise treatment strategies to improve the prognosis due to severe laryngeal functional impairment following traditional surgery and chemora...
Emerging evidence has suggested a potential pathological association between early-onset left-sided colorectal cancer (EOLCC) and metabolic syndrome (MetS). However, the underlying genetic and molecular mechanisms remain insufficiently elucidated. Th...
Early detection of non-small cell lung cancer (NSCLC) can improve survival rates, and plasma proteomics may provide effective tools for risk prediction. The population for this study included 52,913 participants and 2911 plasma proteomics from UK Bio...
Glioblastoma (GBM) is classified into subtypes according to the molecular expression profile; the proneural subtype has a relatively good prognosis, and the mesenchymal type is the most aggressive form with the worst prognosis. GBM undergoes proneura...
Breast cancer is the most common type of cancer in women, and while current treatments can cure the majority of early-stage primary BC cases, recurrence remains a significant challenge. Traditional methods of assessing patient prognosis, such as AJCC...
The tissues-of-origin of circulating cell-free DNA (cfDNA) holds great promise for non-invasive diagnosing cancers, monitoring allograft rejection, and prenatal testing. Many features for inferring the tissues-of-origin of cfDNAs are being revealed f...
Development of acquired therapeutic resistance limits the efficacy of cancer treatments and accounts for therapeutic failure in most patients. How resistance arises, varies across cancer types and differs depending on therapeutic modalities is incomp...
The increasing complexity of cancer diagnostics and treatment selection has placed a growing burden on pathologists, particularly in the evaluation of immunohistochemical (IHC) biomarkers. In gastroesophageal cancers (GEC), both adenocarcinoma and sq...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.